CEO Dinesh Patel Files Intent to Sell Over $9 Million in Company Stock
PTGX has more than doubled off its 52-week low of $33.7.
Summary
CEO Dinesh Patel filed a Form 144 to sell approximately $9.16 million worth of Protagonist Therapeutics stock, primarily acquired through option exercises.
Key Events · Ownership and Investor Activity · PTGX
-
CEO Files Intent to Sell Shares
Dinesh Patel, CEO of Protagonist Therapeutics, Inc., filed a Form 144 indicating an intent to sell 108,273 shares of common stock.
-
Significant Value of Proposed Sale
The proposed sale has an approximate market value of $9.16 million, representing a notable transaction for a key executive.
-
Shares Acquired via Option Exercise
The shares intended for sale were acquired through the exercise of options, a common practice for executive compensation and liquidity.
-
Follows Recent Insider Activity
This filing comes shortly after other Form 4 and Form 144 filings by insiders on January 21, 2026, suggesting a cluster of insider dispositions.
Analysis · PTGX · Life Sciences
Protagonist Therapeutics' CEO, Dinesh Patel, has filed a Form 144 indicating an intent to sell 108,273 shares of common stock, valued at approximately $9.16 million. While the filing notes the shares were acquired through option exercise, this significant disposition by a key executive could be perceived negatively by the market, suggesting a move to monetize compensation or for personal liquidity. This follows other insider activity reported on January 21, 2026, indicating a broader pattern of insider dispositions.
At the time of this filing, PTGX was trading at $83.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.2B. The 52-week trading range was $33.70 to $96.54. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.